Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931636 | 0.90 | LIPE (0.38) | LIPECYP4F2CYP4A11GPR119ACACB | |
| SCHEMBL5931446 | 0.89 | SRD5A2 (0.43) | LIPEGPR119KCNH2ACACB | |
| SCHEMBL5931957 | 0.87 | LIPE (0.44) | LIPECYP4F2CYP4A11GPR119ACACB | |
| SCHEMBL5931569 | 0.86 | LIPE (0.44) | LIPECYP4F2CYP4A11ACACB | |
| SCHEMBL5689840 | 0.86 | KCNH2 (0.39) | LIPECYP4F2CYP4A11GPR119SSTR5 | |
| SCHEMBL5687328 | 0.84 | KMT2A (0.42) | LIPECYP4F2CYP4A11GPR119PARP15 | |
| SCHEMBL5651426 | 0.82 | LIPE (0.44) | LIPEGPR119 | |
| SCHEMBL5931567 | 0.80 | LIPE (0.34) | LIPECYP4F2CYP4A11GPR119KCNH2 | |
| SCHEMBL5687929 | 0.80 | KCNH2 (0.41) | PARP15PARP10PARP2SSTR5KCNH2 | |
| SCHEMBL5689105 | 0.79 | LIPE (0.34) | LIPECYP4F2CYP4A11GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | LIPE 1/4885CYP4F2 2649/4885CYP4A11 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.